CN111603564B - Y-type molecular sieve-doxorubicin nano-drug and preparation method and application thereof - Google Patents
Y-type molecular sieve-doxorubicin nano-drug and preparation method and application thereof Download PDFInfo
- Publication number
- CN111603564B CN111603564B CN202010496401.6A CN202010496401A CN111603564B CN 111603564 B CN111603564 B CN 111603564B CN 202010496401 A CN202010496401 A CN 202010496401A CN 111603564 B CN111603564 B CN 111603564B
- Authority
- CN
- China
- Prior art keywords
- molecular sieve
- drug
- type molecular
- doxorubicin
- nano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a Y-type molecular sieve-doxorubicin (YMS-DOX) nano-drug, and a preparation method and application thereof. The preparation method of the nano-drug is to prepare the Y-type molecular sieve-doxorubicin nano-drug (YMS-DOX) by using a Y-type molecular sieve (YMS) as a carrier and adopting hydrogen bonds and Van der Waals forces to adsorb doxorubicin under the condition of pH 9.0. The nano-drug interacts with human breast cancer cells (MM-231), and the result shows that the Y-type molecular sieve-doxorubicin nano-drug has slow release drug characteristics and can induce tumor cell apoptosis through EPR passive targeting effect; the result shows that the Y-type molecular sieve-doxorubicin nano-drug has the characteristic of reducing the toxic and side effects of the drug through the interaction with dendritic normal cells (DC). The result shows that the Y-type molecular sieve-doxorubicin nano-drug can reduce the toxic and side effects of the chemotherapeutic drugs on normal cells and improve the killing power on tumor cells, and can be applied to the preparation of antitumor drugs.
Description
Technical Field
The invention relates to a nano-drug, in particular to a Y-type molecular sieve-doxorubicin nano-drug and a preparation method thereof, and application of the drug in preparation of breast cancer tumor resistant drugs.
Background
At present, chemotherapy is the most common method of treating tumors. However, although chemotherapy can kill tumor cells, in the treatment process, patients often suffer from physical fatigue, listlessness, sweating and the like due to lack of specific selectivity and great toxic and side effects of the chemotherapy drugs, and the quality of life of the patients is seriously affected.
The advent of nanotechnology has provided a new field of view for early cancer attack, and the use of nanomaterial advantages to load the anticancer drug Doxorubicin (DOX) into drug delivery systems has become a research trend, for example: the nanometer drug delivery system (COPY-DOX) of amphiphilic block polymer loaded DOX is utilized, and fullerene with good water dispersibility is used as a nanometer carrier to prepare the anti-tumor prodrug system with three characteristics of active targeting, photodynamic therapy and pH response chemotherapy. Although nano-drug delivery systems have been largely developed, their slow release properties in tumor microenvironment are not satisfactory and the antitumor effect is weaker than free DOX.
Vallet-region is equal to 2001, and silicon-based mesoporous materials are proposed for drug slow release for the first time, and scientific researchers develop a lot of researches, such as: the influence of the surface property, the pore diameter, the morphology and the like of the mesoporous carrier on the drug carrying and releasing performance of the mesoporous carrier is explored. In view of the characteristics of uniform molecular sieve pore, abundant surface groups, high stability, no toxicity and the like, the application of the preparation in the aspect of prescription production is focused. Comprehensive research results: the mesoporous molecular sieve not only can be used as a drug carrier to become a first choice nano material in clinic, but also provides safety guarantee, which is important to clinical medicine. However, so far, molecular sieve research is limited to slow release of drugs, and no in-depth research on the regulating factors of the anti-tumor drug load and release is performed.
Disclosure of Invention
The invention aims to provide a Y-type molecular sieve-doxorubicin nano-drug, a preparation method and application thereof.
The invention provides a Y-type molecular sieve-doxorubicin nano-drug which is characterized in that the Y-type molecular sieve is used as a carrier, and hydrogen bond and Van der Waals force adsorption doxorubicin are adopted to prepare the Y-type molecular sieve-doxorubicin nano-drug in a pH9.0 environment.
The preparation method of the Y-type molecular sieve-doxorubicin nano-drug comprises the following steps:
(1) Sequentially adding 0.5-1.0mL of ethanol solution and ultrapure water per milligram of Y-type molecular sieve respectively for ultrasonic treatment and high-speed centrifugal washing at 12000rpm for 2 times, then adding 0.5-1.0mL of buffer solution (prepared by citric acid and disodium hydrogen phosphate) with pH of 3.0-12.0 per milligram of Y-type molecular sieve, and performing ultrasonic dispersion for 0.5h to form suspension;
(2) Adding the doxorubicin solution into the Y-type molecular sieve suspension according to the weight ratio of the Y-type molecular sieve to the doxorubicin of 1-10:1, uniformly mixing, placing the mixture on an infrared heating electromagnetic stirrer for reacting for 20 hours at room temperature, centrifuging at a high speed and washing the mixture with ultrapure water for 2-3 times after the reaction is finished until the supernatant is nearly colorless, placing the YMS-DOX nano-drug into a freeze dryer for drying in a dark place for standby, collecting all washing liquid by using a brown reagent bottle, and storing in a dark place.
Preferably, the weight ratio of the Y-type molecular sieve to the doxorubicin is 5:1.
Preferably, the pH value of the buffer solution is 9.0.
Preferably, the high-speed centrifugal rotation speed is 12000rpm.
The Y-type molecular sieve-doxorubicin nano-drug can be applied to preparation of breast cancer tumor resistant drugs.
Compared with the prior art, the invention has the beneficial effects that:
1. the Y-type molecular sieve selected by the invention has the advantages of good biocompatibility, no toxicity, stable chemical property, rich functional groups on the surface and the like;
2. the invention takes the Y-type molecular sieve as a carrier, and the drug loading rate is up to 99.61 percent of YMS-DOX;
3. the activity of the nano-drug to cells is tested by MTT toxicity test, which shows that the nano-drug not only can reduce the toxic and side effects of the chemotherapeutic drug to normal cells, but also can improve the killing power of the chemotherapeutic drug to breast tumor cells.
Drawings
FIG. 1 photograph of nano-drug YMS-DOX under visible light and 365nm ultraviolet light
FIG. 2A ultraviolet-visible absorption spectrum of different pH versus nano drug YMS-DOX loading
FIG. 2B Effect of different pH on nanomedicine YMS-DOX loading
FIG. 3A ultraviolet-visible absorption spectrum of time of action versus nano-drug YMS-DOX
FIG. 3B effect of time of action on the loading of nanomedicine YMS-DOX
FIG. 4A ultraviolet-visible absorption spectrum of different doxorubicin addition levels versus YMS-DOX loading
FIG. 4B effect of different doxorubicin addition amounts on YMS-DOX loading
FIG. 5 ultraviolet-visible absorption spectra of various nanoparticles
FIG. 6 fluorescence spectra of various nanoparticles
FIG. 7 Infrared spectra of various nanoparticles
FIG. 8A Effect of nanocarrier YMS on in vitro culture MM-231 cell Activity
FIG. 8B Effect of nanocarrier YMS on in vitro culture DC cell Activity
FIG. 9A influence of the nano-drug YMS-DOX on the activity of in vitro cultured MM-231 cells
FIG. 9B influence of nanomedicine YMS-DOX on in vitro culture DC cell Activity
Detailed Description
The following are the materials used in the examples:
y-type molecular sieves (YMS, diameter about 10 nm).
Doxorubicin (DOX, C) 27 H 29 NO 11 HCl, molecular weight 579.99) is produced by bio-technology, inc.
Disodium hydrogen phosphate (Na) 2 HPO 4 ·12H 2 O, molecular weight 358.14) and citric acid (C 6 H 8 O 7 ·H 2 O, molecular weight 210.14) is manufactured by Aladin reagent Co., ltd.
Example 1
(1) Accurately weighing 1.0mgY molecular sieve (YMS), respectively ultrasonic high-speed centrifuging with anhydrous ethanol and ultrapure water for 2 times, and standing in 1.0ml buffer solution (C) with pH of 9.0 6 H 8 O 7 ·H 2 O and Na 2 HPO 4 ·12H 2 O blending), ultrasonic dispersing for 0.5 hour to form suspension,
(2) Then adding 0.2mg of Doxorubicin (DOX) into the suspension, uniformly mixing, placing on an infrared heating electromagnetic stirrer, performing light-shielding reaction for 20 hours at room temperature, after the reaction is finished, centrifuging at 12000rpm for 5 minutes at high speed, washing with ultrapure water for three times until the supernatant is nearly colorless, after the washing is finished, placing the Y-type molecular sieve-doxorubicin (YMS-DOX) nano-drug into a freeze dryer for drying for standby. All washings were collected with a brown reagent bottle, stored in a dark place, the mass of DOX adsorbed on YMS nanoparticles was measured, absorbance at 480nm of doxorubicin was detected by uv-vis spectrometry, the amount of DOX adsorbed was calculated, and the mass of doxorubicin adsorbed per mg of YMS was calculated to be about (199.22 ±1.98 μg/mg) microgram.
Example 2
10 parts of 1.0mg YMS were weighed out first by the method of example 1Method (1) followed by washing, 1.0mL of buffer solutions (C) having pH values of 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 11.0 and 12.0 were added, respectively 6 H 8 O 7 ·H 2 O and Na 2 HPO 4 ·12H 2 O blending), ultrasonic dispersing for 0.5 hours, adding 0.2mg of doxorubicin, uniformly mixing, placing on an infrared heating electromagnetic stirrer, reacting for 20 hours at room temperature in a dark place, centrifuging at 12000rpm for 5 minutes at high speed, washing with ultrapure water for three times until the supernatant is nearly colorless, and placing the Y-type molecular sieve-doxorubicin (YMS-DOX) nano-drug in a freeze dryer for drying after the washing is finished. All washes were collected with a brown reagent bottle and stored in the dark for determination of the mass of DOX adsorbed on YMS nanoparticles. The absorbance at 480nm of doxorubicin was detected by ultraviolet-visible light spectrometry, and the DOX loading under different pH conditions was calculated.
The results are shown in fig. 2A and 2B, wherein the pH is in the range of 3.0-12.0, the loading of DOX shows a tendency that the loading of DOX increases and then decreases with the increase of pH, and the inset is a graph of nano-drug supernatant. The DOX loading was maximized at pH 9.0.
Example 3
5 parts of 1.0mg YMS were weighed out, first washed by the method (1) in example 1, and then 1.0ml of buffer solution (C) having a pH of 9.0 was added 6 H 8 O 7 ·H 2 O and Na 2 HPO 4 ·12H 2 O blending), ultrasonic dispersing for 0.5 hours, adding 0.2mg of doxorubicin, uniformly mixing, placing on an infrared heating electromagnetic stirrer, carrying out light-shielding reaction at room temperature for 0.5 hour, 1 hour, 4 hours, 12 hours and 20 hours in sequence, centrifuging at a high speed of 12000rpm for 5 minutes after the reaction is finished, washing with ultrapure water for three times until the supernatant is nearly colorless, and placing the Y-type molecular sieve-doxorubicin (YMS-DOX) nano-drug on a freeze dryer for drying after the washing is finished. All washes were collected with a brown reagent bottle and stored in the dark for determination of the mass of DOX adsorbed on YMS nanoparticles. And detecting absorbance at 480nm of doxorubicin by using an ultraviolet-visible light spectrophotometry, and calculating DOX loading under different action time.
The results are shown in fig. 3A and 3B, with the inset showing the nano-drug supernatant. The DOX adsorption amount increases with time, and the adsorption amount reaches the maximum after 20 hours.
Example 4
6 parts of 1.0mg YMS were weighed out, first washed by the method (1) in example 1, and then 1.0ml of buffer solution (C) having a pH of 9.0 was added 6 H 8 O 7 ·H 2 O and Na 2 HPO 4 ·12H 2 O blending), ultrasonic dispersing for 0.5 hours, then adding 0.1mg, 0.2mg, 0.4mg, 0.5mg, 0.8mg and 1.0mg of doxorubicin respectively, uniformly mixing, placing on an infrared heating electromagnetic stirrer, performing light-proof reaction for 20 hours at room temperature, centrifuging at 12000rpm for 5 minutes after the reaction is finished, washing with ultrapure water for three times until the supernatant is nearly colorless, placing the Y-type molecular sieve-doxorubicin (YMS-DOX) nano-drug on a freeze dryer for drying after the washing is finished, collecting all washing liquid by a brown reagent bottle, storing in a light-proof manner, and determining the mass of DOX adsorbed on YMS nano-particles. The absorbance at 480nm of doxorubicin was detected by ultraviolet-visible light spectrometry, and the DOX loadings at the different doxorubicin addition levels were calculated.
The results are shown in fig. 4A and 4B, which are illustrations of nano-drug supernatant. The DOX loading increased with increasing DOX addition, but the DOX loading was as high as 99.61% when the DOX addition was 200. Mu.g.
Example 5
To confirm whether YMS loading DOX was successful, YMS and YMS-DOX were added to PBS, sonicated for 30 minutes, and then UV-visible absorbance spectra were measured. DOX was also used as a control.
FIG. 5 is an ultraviolet-visible absorption spectrum of the prepared nano-drug, and DOX absorption peak appears at 480nm in the absorption curve of YMS-DOX, indicating that DOX is successfully loaded on the YMS surface.
Example 6
To further confirm successful preparation of YMS-DOX, YMS and YMS-DOX were added to PBS, sonicated for 30 minutes, and then fluorescence excitation and emission spectra were determined. DOX was also used as a control.
FIG. 6 is a fluorescence spectrum of the prepared nano-drug, the excitation wavelength is set to 480nm, the maximum fluorescence emission peak of YMS-DOX appears at 560nm, and the maximum fluorescence emission peak of DOX appears at 590 nm. In contrast to DOX, energy resonance shifts due to fluorescence. The maximum emission wavelength of YMS-DOX blue shifted and the fluorescence intensity decreased, indicating successful loading of DOX onto YMS.
Example 7
To confirm whether doxorubicin was supported on the surface of the Y-type molecular sieve, the lyophilized YMS-DOX was mixed with KBr, ground and tabletted, and the infrared spectrum was measured.
FIG. 7 is an infrared spectrum of the prepared nano-drug, wherein 3456cm -1 The stretching vibration peak of-OH is 1487cm -1 Is at the position of-NH 2 Is a stretching vibration peak of (2). 1471cm in the IR spectrum of YMS-DOX in the figure -1 Characteristic stretching vibration peaks of DOX appear, thereby indicating that DOX has been successfully loaded on YMS.
Example 8
Detecting items: effect of YMS on in vitro culture of MM-231 and DC cell Activity
Human breast cancer cells (MM-231), dendritic Cells (DC) cells (10% FBS/DMEM medium, 5% CO) in logarithmic growth phase 2 At 37 ℃ C.) at 5X 10 per well 3 After the cells were attached to 96-well plates, 200. Mu.L of each experimental group (5.0. Mu.g/mL, 10.0. Mu.g/mL, 25.0. Mu.g/mL, 50.0. Mu.g/mL, 100.0. Mu.g/mL, 200.0. Mu.g/mL, 400.0. Mu.g/mL, 800.0. Mu.g/mL, 1000.0. Mu.g/mL) prepared with 10% FBS/DMEM medium was changed, each group was subjected to a blank control group with untreated MM-231 and DC cells, 6 duplicate wells were provided, 20. Mu.L of 5.0mg/mL PBS solution of MTT was added to each well after 72 hours of culture, the culture was continued for 4 hours, then the old culture solution in the well was discarded, 150. Mu.LDMSO was added to each well, and the mixture was uniformly shaken for 10 minutes, and the on-machine detection by a microplate reader was performed.
FIG. 8A shows the effect on proliferation of YMS and DC cells at different concentrations after 24h, 48h, 72h and 96h, respectively, and FIG. 8B shows the effect on proliferation of YMS and MM-231 cells at different concentrations after 24h, 48h, 72h and 96h, respectively. Compared with a blank cell group, the Y-type molecular sieve YMS has little effect on the activities of two cells of MM-231 and DC under different concentration conditions, and no obvious toxicity is seen when the acting time is prolonged to 96 hours, so that the YMS carrier has biocompatibility;
example 9
Detecting items: effect of nano-drug YMS-DOX on in vitro culture of MM-231 and DC cell Activity
Human breast cancer cells (MM-231) and Dendritic Cells (DC) in logarithmic growth phase (10% FBS/DMEM medium, 5% CO) 2 At 37 ℃ C.) at 5X 10 per well 3 After the cells are inoculated on a 96-well culture plate and adhered to the wall, 200 mu L of 10% FBS/DMEM culture medium is changed to prepare each experimental group (YMS-DOX 0.35 mu g/mL, 0.7 mu g/mL, 1.4 mu g/mL, 2.8 mu g/mL and 6.0 mu g/mL), each group uses untreated MM-231 and DC cells as blank control groups, 6 compound wells are arranged in each group, 20 mu L of 5.0mg/mL MTT PBS solution is added into each well after 72 hours of culture, the culture is continued for 4 hours, then the old culture solution in the well is discarded, 150 mu LDMSO is added into each well, and the mixture is uniformly shaken for 10 minutes for on-machine detection of an enzyme-labelling instrument.
FIG. 9A shows the effect of each drug group on proliferation of MM-231 cells in vitro, and FIG. 9B shows the effect of each drug group on proliferation of DC cells in vitro. From the results, the nano-drug YMS showed different degrees of killing effect on MM-231 cells, and had concentration and time dependence, while being less toxic to DC cells compared to about 2 times less than MM-231 cells. The YMS-DOX nano-drug can effectively kill tumor cells and reduce toxic and side effects on normal cells.
In conclusion, under the action of pH9.0, doxorubicin is physically adsorbed on the surface of the nano-carrier Y-type molecular sieve, so that the YMS-DOX nano-drug is successfully prepared. MTT is used for testing the actions of YMS-DOX, MM-231 and DC cells, which shows that the nano-drug has the property of slow release drug, can effectively kill tumor cells, and gradually enhances the killing power with the prolongation of time and the increase of concentration. Therefore, YMS-DOX can reduce the toxicity and side effects of the chemotherapeutic drugs on normal cells and improve the killing power of the chemotherapeutic drugs on tumor cells, and can be applied to the preparation of breast cancer tumor resistant drugs.
Claims (4)
1. The preparation method of the Y-type molecular sieve-doxorubicin nano-drug is characterized in that the Y-type molecular sieve is used as a carrier, and hydrogen bond and Van der Waals force adsorption doxorubicin are adopted to prepare the Y-type molecular sieve-doxorubicin nano-drug under the condition of pH9.0, and the preparation method comprises the following steps:
(1) Sequentially adding 0.5-1.0mL of ethanol solution and ultrapure water for mixing every milligram of the Y-type molecular sieve, centrifuging and washing at 12000rpm for 2 times, adding 0.5-1.0mL of buffer solution prepared from citric acid and disodium hydrogen phosphate every milligram of the Y-type molecular sieve, and performing ultrasonic dispersion for 0.5h to form a suspension;
(2) Adding the doxorubicin solution into the Y-type molecular sieve suspension according to the weight ratio of the Y-type molecular sieve to the doxorubicin of 1-10:1, uniformly mixing, placing the mixture on an infrared heating electromagnetic stirrer for reacting for 20 hours at room temperature, centrifuging at a high speed after the reaction is finished, washing the mixture with ultrapure water for 2-3 times until the supernatant is nearly colorless, placing the Y-type molecular sieve-doxorubicin nano-drug into a freeze dryer for drying in a dark place for standby, collecting all washing liquid by using a brown reagent bottle, and storing in a dark place.
2. The method for preparing the Y-type molecular sieve-doxorubicin nano-drug according to claim 1, wherein the weight ratio of the Y-type molecular sieve to the doxorubicin is as follows: 5:1.
3. The method for preparing a Y-type molecular sieve-doxorubicin nano-drug according to claim 1, wherein the high-speed centrifugation speed in the step 2 is 12000rpm.
4. The use of a Y-type molecular sieve-doxorubicin nano-drug according to claim 1 in the preparation of an anti-breast cancer tumor drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010496401.6A CN111603564B (en) | 2020-06-03 | 2020-06-03 | Y-type molecular sieve-doxorubicin nano-drug and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010496401.6A CN111603564B (en) | 2020-06-03 | 2020-06-03 | Y-type molecular sieve-doxorubicin nano-drug and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111603564A CN111603564A (en) | 2020-09-01 |
| CN111603564B true CN111603564B (en) | 2023-05-05 |
Family
ID=72200115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010496401.6A Active CN111603564B (en) | 2020-06-03 | 2020-06-03 | Y-type molecular sieve-doxorubicin nano-drug and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111603564B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105106965A (en) * | 2015-09-16 | 2015-12-02 | 山西大学 | Nanometer diamond drug loaded with adriamycin amycin and preparation method and application thereof |
| CN109985247A (en) * | 2019-04-03 | 2019-07-09 | 河南科技学院 | A kind of preparation method of the hybridized metal organic framework compounds for drug release |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4460577A (en) * | 1977-09-30 | 1984-07-17 | Farmitalia Carlo Erba S.P.A. | Pharmaceutical compositions consisting or consisting essentially of liposomes, and processes for making same |
| CN101020058A (en) * | 2007-03-20 | 2007-08-22 | 中国科学院山西煤炭化学研究所 | Application of pure silicon based monodisperse spherical mesoporous molecular sieve in slow release of medicine |
| EP2266964B1 (en) * | 2009-06-22 | 2013-01-09 | KTB Tumorforschungsgesellschaft mbH | Acid-labile trigger units |
| CN104013599B (en) * | 2014-05-28 | 2016-11-23 | 中国科学院生物物理研究所 | The pharmaceutical carrier of a kind of tumour-specific target administration and application thereof |
| CN104606261B (en) * | 2015-03-05 | 2018-02-09 | 潘友长 | A kind of zeolite pharmaceutical composition and its production and use |
| CN105106970B (en) * | 2015-09-16 | 2018-02-06 | 山西大学 | The nanometer diamond medicine preparation and application of high capacity and pH controlled release adriamycins |
| CN110665012B (en) * | 2019-11-20 | 2022-12-06 | 潍坊医学院 | Nano-particles for isolated culture of tumor cells and preparation method thereof |
-
2020
- 2020-06-03 CN CN202010496401.6A patent/CN111603564B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105106965A (en) * | 2015-09-16 | 2015-12-02 | 山西大学 | Nanometer diamond drug loaded with adriamycin amycin and preparation method and application thereof |
| CN109985247A (en) * | 2019-04-03 | 2019-07-09 | 河南科技学院 | A kind of preparation method of the hybridized metal organic framework compounds for drug release |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111603564A (en) | 2020-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kim et al. | Post-synthetic modifications in porous organic polymers for biomedical and related applications | |
| CN107865972B (en) | Preparation method and application of multifunctional membrane-controlled targeting nano-carrier with tracing and targeting drug delivery functions | |
| CN106512023A (en) | Preparation method of difunctional mesoporous silicon ball composite targeted drug delivery system | |
| CN113754793B (en) | Phenylboronic acid grafted chitosan oligosaccharide derivative and preparation method and application thereof | |
| Han et al. | Dual responsive molecularly imprinted polymers based on UiO-66-DOX for selective targeting tumor cells and controlled drug release | |
| Park et al. | Hyaluronic Acid‐Conjugated Mesoporous Silica Nanoparticles Loaded with Dual Anticancer Agents for Chemophotodynamic Cancer Therapy | |
| CN110898229A (en) | Preparation method of double-response nano prodrug for cancer synergistic treatment | |
| CN112439065A (en) | Oxygen-carrying drug-loading self-assembled nano-drug with molecular targeting/sonodynamic treatment and preparation method thereof | |
| CN107096034B (en) | Apigenin-loaded hyaluronic acid targeted nano-assembly and preparation method thereof | |
| CN113855813B (en) | Preparation method and application of ROS-responsive marine fucoidin nanocarrier based on Fenton reaction and AIE effect | |
| CN112057618B (en) | Fe (III) -ART nano particle, preparation method and application thereof | |
| CN111603564B (en) | Y-type molecular sieve-doxorubicin nano-drug and preparation method and application thereof | |
| CN110251672B (en) | Nano diagnosis and treatment agent and preparation method and application thereof | |
| CN110354276B (en) | Prodrug and preparation method and application thereof | |
| Luo et al. | A pH/ROS dual-responsive nanoparticle system for tumor targeting combined chemotherapy/phototherapy | |
| CN115708813B (en) | Multifunctional manganese-based nanoparticle and preparation method and medical application thereof | |
| CN113616806B (en) | Platinum-icodextrin-polycaprolactone macromolecular compound, nano drug-loading system and application thereof | |
| Ugnivenko et al. | Carbon nanotubes in delivery of bioactive substances | |
| CN112870355B (en) | Composite nano-porous platinum-based coordination polymer and preparation method and application thereof | |
| CN111514315B (en) | Method for loading medicine on tumor-targeted amorphous calcium phosphate fluorescent nano composite material | |
| CN112402632B (en) | Nanoscale coordination polymer for radiotherapy sensitization and preparation method and application thereof | |
| Huang et al. | Mesoporous silica nanoparticles with dual-targeting agricultural sources for enhanced cancer treatment via tritherapy | |
| KR101496697B1 (en) | Highly fluorescent carbon nanodot derivatives for simultaneous bioimaging and targeted photodynamic therapy | |
| Yang et al. | Improving the photodynamic therapy of pyropheophorbide a through the combination of hypoxia-sensitive molecule and infrared light-excited d-TiO 2− X nanoparticles | |
| CN111388447B (en) | Adriamycin nano-particles, preparation method and application thereof, and medicine for treating tumors by combining acoustic power with chemical therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |